Twist Bioscience Past Earnings Performance
Past criteria checks 0/6
Twist Bioscience's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 31.1% per year.
Key information
-12.3%
Earnings growth rate
1.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 31.1% |
| Return on equity | -44.2% |
| Net Margin | -66.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Twist Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 313 | -209 | 218 | 91 |
| 30 Jun 24 | 295 | -220 | 213 | 93 |
| 31 Mar 24 | 277 | -192 | 202 | 96 |
| 31 Dec 23 | 262 | -206 | 200 | 99 |
| 30 Sep 23 | 245 | -205 | 190 | 107 |
| 30 Jun 23 | 235 | -209 | 197 | 113 |
| 31 Mar 23 | 228 | -213 | 204 | 125 |
| 31 Dec 22 | 216 | -214 | 204 | 129 |
| 30 Sep 22 | 204 | -218 | 213 | 120 |
| 30 Jun 22 | 184 | -208 | 197 | 110 |
| 31 Mar 22 | 163 | -188 | 178 | 93 |
| 31 Dec 21 | 146 | -165 | 158 | 78 |
| 30 Sep 21 | 132 | -152 | 136 | 69 |
| 30 Jun 21 | 127 | -135 | 125 | 61 |
| 31 Mar 21 | 113 | -123 | 113 | 52 |
| 31 Dec 20 | 101 | -117 | 106 | 47 |
| 30 Sep 20 | 90 | -140 | 103 | 43 |
| 30 Jun 20 | 73 | -147 | 101 | 42 |
| 31 Mar 20 | 66 | -147 | 99 | 40 |
| 31 Dec 19 | 60 | -141 | 91 | 39 |
| 30 Sep 19 | 54 | -108 | 80 | 36 |
| 30 Jun 19 | 47 | -96 | 69 | 31 |
| 31 Mar 19 | 40 | -86 | 59 | 28 |
| 31 Dec 18 | 33 | -77 | 49 | 23 |
| 30 Sep 18 | 25 | -71 | 43 | 20 |
| 30 Jun 18 | 20 | -68 | 39 | 19 |
| 30 Sep 17 | 11 | -59 | 26 | 19 |
| 30 Sep 16 | 2 | -44 | 18 | 18 |
Quality Earnings: 0ME is currently unprofitable.
Growing Profit Margin: 0ME is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0ME is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare 0ME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0ME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 0ME has a negative Return on Equity (-44.16%), as it is currently unprofitable.